Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
All Randomised Patients	STARTED	Placebo	360
All Randomised Patients	STARTED	Nalmefene 18.06 mg	358
All Randomised Patients	COMPLETED	Placebo	337
All Randomised Patients	COMPLETED	Nalmefene 18.06 mg	341
All Randomised Patients	NOT COMPLETED	Placebo	23
All Randomised Patients	NOT COMPLETED	Nalmefene 18.06 mg	17
All Treated Patients	STARTED	Placebo	337
All Treated Patients	STARTED	Nalmefene 18.06 mg	341
All Treated Patients	COMPLETED	Placebo	205
All Treated Patients	COMPLETED	Nalmefene 18.06 mg	194
All Treated Patients	NOT COMPLETED	Placebo	132
All Treated Patients	NOT COMPLETED	Nalmefene 18.06 mg	147

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00812461/flow